<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02903446</url>
  </required_header>
  <id_info>
    <org_study_id>F160315004</org_study_id>
    <nct_id>NCT02903446</nct_id>
  </id_info>
  <brief_title>Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions</brief_title>
  <official_title>Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions in Gout: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Auckland, New Zealand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bone erosions are a common manifestation and feature of structural damage in severe/chronic&#xD;
      tophaceous gout. Management of this destructive and often debilitating gout complication has&#xD;
      focused exclusively on urate-lowering therapy (ULT) to reduce frequency of gout attacks, but&#xD;
      little attention has been given to prevention or reversal of gout related bone erosions and&#xD;
      other structural damage to bone caused by gout. Since there is no known effective treatment&#xD;
      to attenuate or improve structural damage caused by gout, we propose a pilot, controlled,&#xD;
      proof-of-concept study in which denosumab, an FDA approved medication for the treatment of&#xD;
      bone loss, will be added to standard ULT in 20 patients with erosive gout.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A recently published clinical trial with zoledronic acid failed to show an effect in&#xD;
      improving bone erosions among individuals with chronic tophaceous gout, despite improvements&#xD;
      in bone mineral density (BMD) and bone turnover markers. However, it is known that increased&#xD;
      numbers of osteoclasts (cells that absorb bone tissue during growth and healing) in patients&#xD;
      with tophaceous gout are most likely a result of enhanced osteoclast activity as these&#xD;
      patients also have higher circulating levels of the protein receptor activator of nuclear&#xD;
      factor kappa-B ligand (RANKL). RANKL has been identified to affect the immune system and&#xD;
      control bone regeneration and remodeling.&#xD;
&#xD;
      Furthermore, peripheral blood cells and synovial fluid cells taken from patients with erosive&#xD;
      gout preferentially formed osteoclast-like cells in the presence of RANKL. The number of&#xD;
      osteoclasts formed significantly correlates with the number of tophi in gout patients.&#xD;
&#xD;
      Denosumab (Prolia®) is a fully human monoclonal antibody with a high affinity for RANKL that&#xD;
      can bind and neutralize the activity of human RANKL. Given the relevance of RANKL in the&#xD;
      mechanism of gouty erosions,a central hypothesis of this pilot study is that denosumab is&#xD;
      more likely to precisely target RANKL and the mechanism of gouty erosions than zoledronic&#xD;
      acid.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CT Bone Erosion Score</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in the foot CT bone erosion score from baseline to 12 months. A total of 14 bones of the foot are scored. Each bone of the scored separately on a scale from 0 to 10, based on the proportion of eroded bone compared with the 'assessed bone volume', judged on all available images-0: no erosion; 1: 1-10% of bone eroded; 2: 11-20% bone eroded; 3:21-30% of bone eroded; 4: 31-40% of bone eroded; 5: 51-60% bone eroded; 7:61-70% of bone eroded; 8: 71-80% of bone eroded; 9: 81-90% bone eroded; 10:&gt;=91% of bone eroded.&#xD;
Higher score indicates worsening of erosion. Score ranges from 0 to 140.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in Bone Reabsorption</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in bone reabsorption as measured by serum carboxy-terminal collagen crosslinks (CTX) levels (pg/mL) over 12 months. Lower values represent varying degrees of suppression of normal bone turnover.&#xD;
The reference ranges for C-terminal telopeptide in serum are as follows:&#xD;
Female (premenopausal): 40-465 pg/mL Female (postmenopausal): 104-1008 pg/mL Male: 60-700 pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Subject Reported Functional Status (Disability)</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in subject reported functional status (disability) by Health Assessment Questionnaire (HAQ) will be assessed from baseline over 12 months. 0 to 1 are generally considered to represent mild to moderate difficulty, 1 to 2 moderate to severe disability, and 2 to 3 severe to very severe disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Reported Change in Physical Health</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Subject reported change in physical and mental health by Short Form Health Survey (SF-12) scores assessed from baseline over 12 months. Range 0-100 with higher scores representing better self-reported health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Reported Change in Mental Health</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Subject Reported Change in Mental Health on SF-12 mental component form. Range 0-100 with higher scores representing better self-reported health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Pain</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Assessment of pain score by visual analogue scale (VAS) reported from baseline over 12 months. Range 0-10 with higher scores representing more pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard urate lowering therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Prolia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 30 years or older and able to provide informed consent&#xD;
&#xD;
          -  Diagnosis of gout according to the American College of Rheumatology (ACR) / European&#xD;
             League Against Rheumatism (EULAR) classification criteria&#xD;
&#xD;
          -  Radiographic foot bone erosion attributable to gout and confirmed by a radiologist&#xD;
&#xD;
          -  Serum urate of ≤ 5 mg/dL (300 µmol/L) or less*&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with bisphosphonates in the preceding 2 years&#xD;
&#xD;
          -  Any prior treatment with denosumab&#xD;
&#xD;
          -  Women of childbearing potential, who are not currently using birth control, are&#xD;
             pregnant, planning to become pregnant, or are breast-feeding&#xD;
&#xD;
          -  Men planning to conceive in the next 12 months&#xD;
&#xD;
          -  Unstable systemic medical condition&#xD;
&#xD;
          -  Uncontrolled hyperthyroidism&#xD;
&#xD;
          -  Uncontrolled hypothyroidism&#xD;
&#xD;
          -  History of Addison disease&#xD;
&#xD;
          -  History of osteomalacia&#xD;
&#xD;
          -  History of osteonecrosis of the jaw (ONJ)&#xD;
&#xD;
          -  History of atypical femur fracture&#xD;
&#xD;
          -  History of tooth extraction, jaw surgery, dental implants, or other dental surgery&#xD;
             within the prior 6 months&#xD;
&#xD;
          -  History of anorexia nervosa, bulimia (by history or physical) or obvious malnutrition.&#xD;
&#xD;
          -  Invasive dental work planned in the next 2 years&#xD;
&#xD;
          -  History of Paget's disease of bone&#xD;
&#xD;
          -  Other bone diseases which affect bone metabolism&#xD;
&#xD;
          -  Vitamin D deficiency [25(OH) vitamin D level &lt; 20 ng/mL (&lt;49.9 nmol/L)]†&#xD;
&#xD;
          -  Hypercalcemia&#xD;
&#xD;
          -  Elevated transaminases ≥ 2.0 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Elevated total bilirubin &gt; 1.5x ULN&#xD;
&#xD;
          -  History of any solid organ or bone marrow transplant&#xD;
&#xD;
          -  Malignancy within the last 5 years (except cervical carcinoma in situ or basal cell&#xD;
             carcinoma)&#xD;
&#xD;
          -  Hypocalcemia&#xD;
&#xD;
          -  Poorly tolerant of ULT including allopurinol, febuxostat, or probenecid&#xD;
&#xD;
          -  Estimated glomerular filtration rate &lt; 30 mL/minute/1.73 m^2&#xD;
&#xD;
          -  Current use of any biological therapy (eg. infliximab, etanercept, adalimumab, etc.)&#xD;
&#xD;
          -  Treatment history with pegloticase or another recombinant uricase&#xD;
&#xD;
          -  Recipient of an investigational drug within 4 weeks prior to study drug administration&#xD;
             or plans to take an investigational agent during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 13, 2016</study_first_submitted>
  <study_first_submitted_qc>September 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <results_first_submitted>May 8, 2021</results_first_submitted>
  <results_first_submitted_qc>August 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2021</results_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Angelo L. Gaffo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT02903446/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Potential study participants were screened for enrollment at rheumatology clinics located at the University of Alabama at Birmingham and the University of Auckland. Participants were recruited between March 2017 and May 2019.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care&#xD;
Denosumab: Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Standard urate lowering therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care&#xD;
Denosumab: Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Standard urate lowering therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="15"/>
                    <measurement group_id="B2" value="63" spread="9.4"/>
                    <measurement group_id="B3" value="65.0" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>European descent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maori</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Urate</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.3" spread="0.5"/>
                    <measurement group_id="B2" value="4.2" spread="0.7"/>
                    <measurement group_id="B3" value="4.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated glomerular filtration rate</title>
          <units>mL/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.5" spread="32"/>
                    <measurement group_id="B2" value="72" spread="15.3"/>
                    <measurement group_id="B3" value="74.2" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CT Erosion Score (range 0-140 total of 14 bones)</title>
          <description>Change in the foot CT bone erosion score from baseline to 12 months. A total of 14 bones of the foot are scored. Each bone of the scored separately on a scale from 0 to 10, based on the proportion of eroded bone compared with the 'assessed bone volume', judged on all available images-0: no erosion; 1: 1-10% of bone eroded; 2: 11-20%, etc.&#xD;
Higher score indicate worsening of erosion.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.6" spread="5.4"/>
                    <measurement group_id="B2" value="7.0" spread="5.1"/>
                    <measurement group_id="B3" value="6.8" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum CTX</title>
          <description>Measure of the amount carboxy-terminal collagen crosslinks (CTX) in serum</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="316.6" spread="152.6"/>
                    <measurement group_id="B2" value="286.9" spread="111.5"/>
                    <measurement group_id="B3" value="303.4" spread="133.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health Assessment Questionnaire -Disability Index Total (range from 0-3.0)</title>
          <description>0 to 1 are generally considered to represent mild to moderate difficulty, 1 to 2 moderate to severe disability, and 2 to 3 severe to very severe disability.</description>
          <units>HAQ Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.36" spread="0.61"/>
                    <measurement group_id="B2" value="0.39" spread="0.44"/>
                    <measurement group_id="B3" value="0.38" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Short Form Survey (SF-12) physical component score (range 0-100)</title>
          <description>The SF-12 measures eight concepts commonly represented in widely used surveys: physical functioning. Subject reported change in physical and mental health by Short Form Health Survey (SF-12) scores assessed from baseline over 12 months. Range 0-100 with higher scores representing better self-reported health.</description>
          <units>SF-12 score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.6" spread="11.9"/>
                    <measurement group_id="B2" value="43.9" spread="7.3"/>
                    <measurement group_id="B3" value="43.8" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Short Form Survey (SF-12) mental component score (range 0-100)</title>
          <description>Subject reported change in physical and mental health by Short Form Health Survey (SF-12) scores assessed from baseline over 12 months. Range 0-100 with higher scores representing better self-reported health.</description>
          <units>SF-12 score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="4.2"/>
                    <measurement group_id="B2" value="55.1" spread="10.4"/>
                    <measurement group_id="B3" value="56.3" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Analogue Pain Score (range 0-10)</title>
          <description>A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values (0-10)</description>
          <units>visual analog pain scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" spread="3.7"/>
                    <measurement group_id="B2" value="1.3" spread="1.5"/>
                    <measurement group_id="B3" value="1.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CT Bone Erosion Score</title>
        <description>Change in the foot CT bone erosion score from baseline to 12 months. A total of 14 bones of the foot are scored. Each bone of the scored separately on a scale from 0 to 10, based on the proportion of eroded bone compared with the 'assessed bone volume', judged on all available images-0: no erosion; 1: 1-10% of bone eroded; 2: 11-20% bone eroded; 3:21-30% of bone eroded; 4: 31-40% of bone eroded; 5: 51-60% bone eroded; 7:61-70% of bone eroded; 8: 71-80% of bone eroded; 9: 81-90% bone eroded; 10:&gt;=91% of bone eroded.&#xD;
Higher score indicates worsening of erosion. Score ranges from 0 to 140.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care&#xD;
Denosumab: Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard urate lowering therapy</description>
          </group>
        </group_list>
        <measure>
          <title>CT Bone Erosion Score</title>
          <description>Change in the foot CT bone erosion score from baseline to 12 months. A total of 14 bones of the foot are scored. Each bone of the scored separately on a scale from 0 to 10, based on the proportion of eroded bone compared with the 'assessed bone volume', judged on all available images-0: no erosion; 1: 1-10% of bone eroded; 2: 11-20% bone eroded; 3:21-30% of bone eroded; 4: 31-40% of bone eroded; 5: 51-60% bone eroded; 7:61-70% of bone eroded; 8: 71-80% of bone eroded; 9: 81-90% bone eroded; 10:&gt;=91% of bone eroded.&#xD;
Higher score indicates worsening of erosion. Score ranges from 0 to 140.</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="5.4"/>
                    <measurement group_id="O2" value="7.0" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in Bone Reabsorption</title>
        <description>Change in bone reabsorption as measured by serum carboxy-terminal collagen crosslinks (CTX) levels (pg/mL) over 12 months. Lower values represent varying degrees of suppression of normal bone turnover.&#xD;
The reference ranges for C-terminal telopeptide in serum are as follows:&#xD;
Female (premenopausal): 40-465 pg/mL Female (postmenopausal): 104-1008 pg/mL Male: 60-700 pg/mL</description>
        <time_frame>Baseline, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care&#xD;
Denosumab: Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard urate lowering therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in Bone Reabsorption</title>
          <description>Change in bone reabsorption as measured by serum carboxy-terminal collagen crosslinks (CTX) levels (pg/mL) over 12 months. Lower values represent varying degrees of suppression of normal bone turnover.&#xD;
The reference ranges for C-terminal telopeptide in serum are as follows:&#xD;
Female (premenopausal): 40-465 pg/mL Female (postmenopausal): 104-1008 pg/mL Male: 60-700 pg/mL</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.6" spread="143.1"/>
                    <measurement group_id="O2" value="324.1" spread="113.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Subject Reported Functional Status (Disability)</title>
        <description>Change in subject reported functional status (disability) by Health Assessment Questionnaire (HAQ) will be assessed from baseline over 12 months. 0 to 1 are generally considered to represent mild to moderate difficulty, 1 to 2 moderate to severe disability, and 2 to 3 severe to very severe disability.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care&#xD;
Denosumab: Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard urate lowering therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Subject Reported Functional Status (Disability)</title>
          <description>Change in subject reported functional status (disability) by Health Assessment Questionnaire (HAQ) will be assessed from baseline over 12 months. 0 to 1 are generally considered to represent mild to moderate difficulty, 1 to 2 moderate to severe disability, and 2 to 3 severe to very severe disability.</description>
          <units>Difference in HAQ score from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".33" spread=".30"/>
                    <measurement group_id="O2" value=".11" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Reported Change in Physical Health</title>
        <description>Subject reported change in physical and mental health by Short Form Health Survey (SF-12) scores assessed from baseline over 12 months. Range 0-100 with higher scores representing better self-reported health.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care&#xD;
Denosumab: Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard urate lowering therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Reported Change in Physical Health</title>
          <description>Subject reported change in physical and mental health by Short Form Health Survey (SF-12) scores assessed from baseline over 12 months. Range 0-100 with higher scores representing better self-reported health.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" spread="12.6"/>
                    <measurement group_id="O2" value="52.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Reported Change in Mental Health</title>
        <description>Subject Reported Change in Mental Health on SF-12 mental component form. Range 0-100 with higher scores representing better self-reported health</description>
        <time_frame>Baseline, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care&#xD;
Denosumab: Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard urate lowering therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Reported Change in Mental Health</title>
          <description>Subject Reported Change in Mental Health on SF-12 mental component form. Range 0-100 with higher scores representing better self-reported health</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7" spread="6.7"/>
                    <measurement group_id="O2" value="53.1" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Pain</title>
        <description>Assessment of pain score by visual analogue scale (VAS) reported from baseline over 12 months. Range 0-10 with higher scores representing more pain.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care&#xD;
Denosumab: Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard urate lowering therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Pain</title>
          <description>Assessment of pain score by visual analogue scale (VAS) reported from baseline over 12 months. Range 0-10 with higher scores representing more pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="3.1"/>
                    <measurement group_id="O2" value="1.2" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care&#xD;
Denosumab: Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Standard urate lowering therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Medra</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastro-esophageal reflux</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Esophageal refulx</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Joint Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cramps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angelo Gaffo, MD; Associate Professor</name_or_title>
      <organization>UNIVERSITY OF ALABAMA AT BIRMINGHAM</organization>
      <phone>205-996-6086</phone>
      <email>agaffo@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

